Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ligand Set For Partnership Opportunities After Completing On Pfenex

Sets Out Strategy And Revenue Drivers After Finalizing $500m Deal

Executive Summary

Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.

You may also be interested in...



Deal Watch: Private Equity-Backed Covis Bids To Buy Troubled AMAG

Following a strategic review, AMAG goes to Covis. Vincera goes public in merger with blank check company, has pending cancer deal with Bayer.

Clock Ticks On Pfenex Teriparatide Equivalence Windfall

Pfenex has less than two months for an “A” designation for therapeutic equivalence for to be granted for its Bonsity (teriparatide) 505(b)(2) product by the US FDA if it wishes to realize maximum value under the companies’ partnership agreement with Alvogen.

Sandoz Hits Back At Biosimilar Misinformation

Pierre Bourdage, global head of biopharmaceuticals at Sandoz, has hit back at false statements and misleading claims around biosimilars that persist despite mounting evidence to the contrary.

Topics

Related Companies

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel